



(11) **EP 3 515 938 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
30.04.2025 Bulletin 2025/18

(45) Date of publication and mention
of the grant of the patent:
08.01.2025 Bulletin 2025/02

(21) Application number: **16916449.8**

(22) Date of filing: **21.09.2016**

(51) International Patent Classification (IPC):
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 35/00 ^(2006.01) **C12N 15/13** ^(2006.01)
C12N 15/63 ^(2006.01) **C12N 5/10** ^(2006.01)
C12N 5/20 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07K 16/2818; A61K 2039/505;
C07K 2317/24; C07K 2317/33; C07K 2317/34;
C07K 2317/56; C07K 2317/74; C07K 2317/76;
C07K 2317/92

(86) International application number:
PCT/CN2016/099576

(87) International publication number:
WO 2018/053709 (29.03.2018 Gazette 2018/13)

(54) **MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)**

MONOKLONALE ANTIKÖRPER GEGEN DEN PROGRAMMIERTEN TOD 1 (PD-1)

ANTICORPS MONOCLONAUX DIRIGÉS CONTRE LA MORT PROGRAMMÉE 1 (PD -1)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
31.07.2019 Bulletin 2019/31

(60) Divisional application:
24184760.7 / 4 450 616

(73) Proprietors:
• **CSTONE PHARMACEUTICALS**
KY1-1205 Grand Cayman (KY)
• **CSTONE PHARMACEUTICALS (SUZHOU) CO.,**
LTD.
Jiangsu 215123 (CN)
• **CSTONE PHARMACEUTICALS (SHANGHAI) CO.,**
LTD.
Shanghai 200000 (CN)

(72) Inventors:
• **ZHENG, Yong**
Shanghai 201203 (CN)
• **LI, Jing**
Lexington, Massachusetts 02420 (US)

- **GOLOLOBOV, Gennady**
Gaithersburg, Maryland 20878 (US)
- **ZHANG, Xinhua**
Shanghai 201209 (CN)
- **YANG, Baotian**
Shanghai 200137 (CN)
- **TANG, Zhewei**
Shanghai 200136 (CN)
- **LI, Dong**
Shanghai 200444 (CN)
- **XU, Jianqing**
Shanghai 201200 (CN)
- **WANG, Zhuozhi**
Millbrae, California 94030 (US)

(74) Representative: **Engelhard, Markus**
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München (DE)

(56) References cited:
WO-A1-2013/148250 WO-A1-2015/112900
WO-A1-2015/112900 WO-A2-2016/077397
WO-A2-2016/127179 CA-A1- 2 955 541

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 515 938 B8

- | | |
|--|---|
| <ul style="list-style-type: none">• ANONYMOUS: "Assessment report OPDIVO International non-proprietary name: nivolumab Procedure No. EMEA/H/C/003985/0000", EMA/CHMP/76688/2015, 23 April 2015 (2015-04-23), pages 1 - 130, XP093186112 | <ul style="list-style-type: none">• WANG, C. ET AL.: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOL RES., vol. 2, 28 May 2014 (2014-05-28), XP055206944 |
|--|---|